Online Inquiry

Hit-To-Lead Services in Radiopharmaceutical Discovery

At Rdcthera, radiopharmaceuticals are our specialty, and we offer specifically tailored CRO services. Our main business is providing integrated hit-to-lead services targeted for the discovery and development of radiopharmaceuticals.

Hit-To-Lead Introduction

A lead compound is one that is identified through an initial screening of a library of compounds and subsequently evaluated for its binding affinity, specificity, and potential for therapeutic application in the discovery of radiopharmaceuticals. These are starting points for the further optimization and development of leads in such a manner that properties in relation to clinical requirements are improved.

Hit-to-Lead Process

The hit-to-lead is such an important stage in drug discovery. It proceeds from the initial hits arising from high-throughput screenings through evaluation and optimization into lead compounds. It is marked by serially rigorous testing through binding affinity studies, both in vitro and in vivo studies for efficacy, and early toxicity assessments. It is aimed at the selection and optimization of compounds that have the greatest likelihood of succeeding in the latter part of drug development.

Fig 1. Drug discovery process.

Our Hit-to-Lead CRO Services

Rdcthera offers comprehensive hit-to-lead CRO services in the area of early stage radiopharmaceutical discovery to help our clients accelerate their drug development programmes and smooth the road to market.

  • Our Hit-to-Lead Expertise

Our comprehensive drug discovery CRO services provide hit generation, hit expansion and lead compound optimization, including biology, DMPK, in vivo pharmacology, pharmacy and safety assessment. Our biochemistry teams work collaboratively to bring candidate compounds to the clinic. Utilising our integrated drug discovery approach ensures high efficiency and quality in your project. Our services include

  • In vivo early pharmacokinetics
  • In vitro early ADMET
  • Early safety assessment
  • Medicinal chemistry
  • Structure based drug design
  • Computer-assisted drug design
  • Biophysics
  • Molecular modelling
  • Customized Hit-to-Lead Services

Rdcthera understands that every radiopharmaceutical development project is unique, and therefore offers tailored services to meet the unique needs of our clients. Tailored screening parameters and synthesis of radiolabelled compounds are used to achieve the best possible results in terms of lead identification and optimisation.

  • Our Technology Platform

Our state-of-the-art integrated technology platform pools the most advanced tools in radiochemistry, molecular imaging, and bioinformatics, allowing for seamless transitions from hit identification to lead optimization. The holistic strategy guarantees all steps in the hit-to-lead process are connected, making it a coherent and efficient workflow that accelerates the discovery and development of radiopharmaceuticals.

Contact us to learn more about our services for the support of your radiopharmaceutical discovery projects. Our team is available to assist you with inquiries and provide all the needed details on our offers. In choosing Rdcthera as your partner in CRO, you engage a team that has its focus set on excellence in radiopharmaceutical discovery and development. Let us help you transform innovative ideas into breakthrough therapies.

For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy